Skip to main content
Clinical Trials/CTRI/2024/02/063314
CTRI/2024/02/063314Not yet recruitingUnknown

Comparative Evaluation of Therapeutic Efficacy of Autologous Serum Therapy versus Injection Histaglobulin in Chronic Idiopathic Urticaria: An Open-label Randomized Control Trial

AIIMS, Rishikesh1 site in 1 country92 target enrollmentStarted: March 11, 2024Last updated:
Conditions

Trial Snapshot

Phase
Unknown
Status
Not yet recruiting
Sponsor
Enrollment
92
Locations
1
Primary Endpoint
To compare the therapeutic efficacy of AST and injection Histaglobulin in patients of chronic idiopathic urticaria on the basis of change in Urticaria Activity Score and Dermatology Life Quality Index from baseline after 12 weeks post completion of either modality.

Study Overview

Brief Summary

The recruitment will start after CTRI registration. Only patients of Indian ethnicity visiting Dermatology OPD AIIMS, Rishikesh for management of chronic urticaria who are willing to give consent for the study will be recruited .

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 18 years or above patient willing to give consent and not having any contraindication for the procedure.

Exclusion Criteria

  • Active microbial infection, Pregnancy or Lactation, Hypersensitivity to Histaglob injection, Immunosuppressed cases or uncontrolled Diabetes mellitus.

Outcomes

Primary Outcomes

To compare the therapeutic efficacy of AST and injection Histaglobulin in patients of chronic idiopathic urticaria on the basis of change in Urticaria Activity Score and Dermatology Life Quality Index from baseline after 12 weeks post completion of either modality.

Time Frame: At baseline, then at 10 weeks and after 12 weeks from the point of last injection given in either group

Secondary Outcomes

  • To compare the reduction of antihistamine usage by patient on either of these modalities of therapy for chronic urticaria.(One year duration)

Investigators

Sponsor
AIIMS, Rishikesh
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

Dr Sushantika

AIIMS, Rishikesh

Study Sites (1)

Loading locations...

Similar Trials